CD8+ T cells per gram of tumor increased in anti-CD47 manner; almost every therapeutic group which received anti-CD47 in the therapeutic regimen showed a significant increase in CD8+ T cells compared to groups which didn't receive it (Fig. 5B). This evidence concerns the gene CD47 and neoplasm.